文献速递冠心病

超薄支架与常规第二代药物洗脱支架的长期随访:随机对照试验的系统综述与荟萃分析

Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Eur Heart J · 2021-01-01

加权平均随访2.5年,超薄支架组靶病变失败风险降低15%(RR 0.85,95%CI 0.76-0.96,P=0.008),主要由临床驱动的靶病变血运重建减少25%驱动(RR 0.75,95%CI 0.62-0.92,P=0.005),而心肌梗死、支架血栓、心源性死亡和全因死亡风险无显著差异。

要点

  • 超薄支架较常规第二代薄支架降低长期靶病变失败风险15%。
  • 获益主要来自临床驱动的靶病变血运重建减少25%。
  • 心肌梗死、支架血栓、心源性死亡和全因死亡风险无显著差异。

核心结论

  • 在平均2.5年随访中,超薄支架药物洗脱支架较常规第二代薄支架降低靶病变失败风险,主要由临床驱动的靶病变血运重建减少驱动,而心肌梗死、支架血栓、心源性死亡和全因死亡风险相似。

主要发现

  • 超薄支架组长期靶病变失败风险降低15%(RR 0.85,95%CI 0.76-0.96,P=0.008)。
  • 临床驱动的靶病变血运重建风险降低25%(RR 0.75,95%CI 0.62-0.92,P=0.005)。
  • 心肌梗死、支架血栓、心源性死亡和全因死亡风险在两组间无显著差异。

临床怎么用

  • 在经皮冠状动脉介入治疗血运重建中,超薄支架(≤70 µm)可作为常规第二代薄支架的替代选择,以降低长期靶病变失败和临床驱动的靶病变血运重建风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Contemporary 2nd-generation thin-strut drug-eluting stents (DES) are considered standard of care for revascularization of patients undergoing percutaneous coronary intervention. A previous meta-analysis of 10 randomized controlled trials (RCTs) with 11 658 patients demonstrated a 16% reduction in the 1-year risk of target lesion failure (TLF) with ultrathin-strut DES compared with conventional 2nd-generation thin-strut DES. Whether this benefit is sustained longer term is not known, and newer trial data may inform these relative outcomes. We therefore sought to perform an updated systematic review and meta-analysis of RCTs comparing clinical outcomes with ultrathin-strut DES (≤70 µm strut thickness) with conventional 2nd-generation thin-strut DES. METHODS AND RESULTS: We performed a random-effects meta-analysis of all RCTs comparing ultrathin-strut DES to conventional 2nd-generation thin-strut DES. The pre-specified primary endpoint was long-term TLF, a composite of cardiac death, myocardial infarction (MI), or clinically driven target lesion revascularization (CD-TLR). Secondary endpoints included the components of TLF, stent thrombosis (ST), and all-cause death. There were 16 eligible trials in which 20 701 patients were randomized. The weighted mean follow-up duration was 2.5 years. Ultrathin-strut DES were associated with a 15% reduction in long-term TLF compared with conventional 2nd-generation thin-strut DES [relative risk (RR) 0.85, 95% confidence interval (CI) 0.76-0.96, P = 0.008] driven by a 25% reduction in CD-TLR (RR 0.75, 95% CI 0.62-0.92, P = 0.005). There were no significant differences between stent types in the risks of MI, ST, cardiac death, or all-cause mortality. CONCLUSIONS: At a mean follow-up of 2.5 years, ultrathin-strut DES reduced the risk of TLF, driven by less CD-TLR compared with conventional 2nd-generation thin-strut DES, with similar risks of MI, ST, cardiac death, and all-cause mortality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Madhavan MV, Howard JP, Naqvi A, et al. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2021. PMID: 34002202. doi:10.1093/eurheartj/ehab280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。